Clinical Trials Logo
  1. Home
  2. Solid Carcinoma
  3. NCT04264975

Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology

Solid Carcinoma Clinical Trial

Official title:
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology

Clinical Trial Summary

This is an open label, single-center, non-randomized clinical trial on utilization of microbiome as biomarkers and therapeutics in immuno-oncology.

This research consists of two parts:

part 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for advanced solid tumor

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04264975
Study type Interventional
Source Asan Medical Center
Contact Sook Ryun Park, M.D, Ph D
Phone +82-2-3010-3210
Email srpark@amc.seoul.kr
Status Recruiting
Phase N/A
Start date June 4, 2018
Completion date April 30, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Completed NCT05054374 - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT06051214 - Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk N/A
Not yet recruiting NCT05533983 - FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy N/A
Completed NCT03590808 - Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor N/A
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Recruiting NCT05678010 - A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer Phase 1
Recruiting NCT05346484 - A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors Phase 1
Recruiting NCT01312701 - Study of Blood Immune Cells in Cancer Patients Compared to Controls N/A
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Completed NCT04644874 - Geriatric Oncology Screening of Older Patients With Solid Cancers
Recruiting NCT04443088 - An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT04545827 - Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Phase 1
Completed NCT04747249 - Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19 N/A
Completed NCT03536728 - Oral AMXT 1501 Dicaprate in Combination With DFMO Phase 1
Active, not recruiting NCT02974738 - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Phase 1
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1